Christina Willwerth - Jul 19, 2021 Form 4 Insider Report for Flexion Therapeutics Inc (FLXN)

Role
Chief Strategy Officer
Signature
/s/ Mark S. Levine, Attorney-in-Fact
Stock symbol
FLXN
Transactions as of
Jul 19, 2021
Transactions value $
-$25,445
Form type
4
Date filed
7/20/2021, 08:51 PM
Next filing
Nov 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLXN Common Stock Sale -$25.4K -3.95K -2.72% $6.45 141K Jul 19, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover tax withholding obligations associated with the vesting of restricted stock unit award granted to the Reporting Person on July 16, 2020.
F2 The weighted average sale price for the transaction reported was $6.45. The shares were sold at a range of prices between $6.28 and $6.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.